Guardant Health Inc. (NASDAQ:GH) is one of the most promising stocks under $100 to buy. On March 16, Guardant Health announced the launch of its Shield multi-cancer detection/MCD test in several Asian markets through a first-of-its-kind partnership with Manulife. This methylation-based blood test is designed to detect ten common types of cancer (including lung, breast, colorectal, and liver) in individuals aged 45 or older who are at typical risk.

Starting in April, eligible Manulife customers in Hong Kong, Singapore, and the Philippines will be the first in the region to gain access to this screening technology. The collaboration aims to address significant unmet health needs in Asia, where cancer remains a leading cause of death, and early detection is vital for survivorship.

By requiring only a simple blood draw, the Shield MCD test seeks to increase screening participation rates and identify malignancies at earlier, more treatable stages. In the US, the technology has already received Breakthrough Device Designation from the FDA based on its performance in predicting the presence and origin of cancer tissue. This move marks a major milestone in Guardant Health Inc.’s (NASDAQ:GH) global expansion of precision oncology tools.

Copyright: epstock / 123RF Stock Photo

Guardant Health Inc. (NASDAQ:GH) is a precision oncology company in the healthcare industry. It provides blood & tissue tests and data sets; particularly the Guardant360 CDx, Guardant360 Liquid, Guardant Reveal, and Guardant360 Tissue test.

While we acknowledge the potential of GH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.